To evaluate the feasibility, safety, and efficacy of ultrasound-guided transperineal laser ablation (TPLA) as a new minimally invasive surgical therapy (MIST) for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).
Materials and methods
Under local anesthesia and conscious sedation up to two laser fibers for each prostatic lobe were inserted under US-guidance by a percutaneous approach. TPLA was performed using a continuous wave diode laser (SoracteLite-EchoLaserX4) able to generate a light-induced thermal heating and subsequent coagulative necrosis of the prostatic tissue. Patients were evaluated at 3, 6, and 12 months after TPLA.
Twenty-two consecutive patients were prospectively enrolled (median age 61.9 years). All procedures were well tolerated and no procedural complications were recorded. Median catheterization time was 7 days, while the median hospitalization time was 1 day. Three out of twenty-two patients (13.6%) experienced acute urinary retention and two (9.1%) of them urinary tract infection requiring major antibiotic treatment. At 3, 6, and 12 months, median prostate volume significantly decreased by a − 21.3%, − 29%, and − 41%, respectively. At the same time point, median IPSS was 8 (− 63.6%), 5 (− 74%), and 6 (− 75%), while median QoL score was 1 in all the scheduled timepoints of follow-up. The median postoperative Qmax at 3, 6, and 12 months improved by + 57.8%, + 98%, and + 115.8%, respectively. Ejaculatory function was preserved in 21 out of 22 patients (95.5%).
TPLA of the prostate appears to be a promising MIST for BPH. Long-term results and comparative studies against standard treatments are warranted before implementations of this technique in the urologist’s armamentarium.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
Availability of data and material
All data are available if request.
Thorpe A, Neal D (2003) Benign prostatic hyperplasia. Lancet. https://doi.org/10.1016/S0140-6736(03)13073-5
Wei JT, Calhoun E, Jacobsen SJ (2008) Urologic diseases in America project: benign prostatic hyperplasia. J Urol. https://doi.org/10.1016/j.juro.2008.03.141
Bhatt NR, Davis NF, Witjes WP et al (2020) Quality of life with pharmacological treatment in patients with benign prostatic enlargement: results from the Evolution European Prospective Multicenter Multi-National Registry Study. World J Urol. https://doi.org/10.1007/s00345-020-03219-7
Verhamme KMC, Dieleman JP, Bleumink GS, Bosch JLHR, Stricker BHC, Sturkenboom MCJM (2003) Treatment strategies, patterns of drug use and treatment discontinuation in men with luts suggestive of benign prostatic hyperplasia: the triumph project. Eur Urol. https://doi.org/10.1016/S0302-2838(03)00376-2
Gratzke C, Bachmann A, Descazeaud A et al (2015) EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. https://doi.org/10.1016/j.eururo.2014.12.038
Leonardo C, Lombardo R, Cindolo L et al (2020) What is the standard surgical approach to large volume BPe? Systematic review of existing randomized clinical trials. Minerva Urol e Nefrol. https://doi.org/10.23736/S0393-2249.19.03589-6
Magistro G, Chapple CR, Elhilali M et al (2017) Emerging minimally invasive treatment options for male lower urinary tract symptoms [figure presented]. Eur Urol. https://doi.org/10.1016/j.eururo.2017.07.005
Gu C, Zhou N, Gurung P et al (2020) Lasers versus bipolar technology in the transurethral treatment of benign prostatic enlargement: a systematic review and meta-analysis of comparative studies. World J Urol. https://doi.org/10.1007/s00345-019-02852-1
Gravas S, Bachmann A, Reich O, Roehrborn CG, Gilling PJ, De La Rosette J (2011) Critical review of lasers in benign prostatic hyperplasia (BPH). BJU Int. https://doi.org/10.1111/j.1464-410X.2010.09954.x
Mattiasson A, Wagrell L, Schelin S et al (2007) Five-year follow-up of feedback microwave thermotherapy versus TURP for clinical BPH: a Prospective Randomized Multicenter Study. Urology. https://doi.org/10.1016/j.urology.2006.08.1115
Hammadeh MY, Philp T (2003) Transurethral electrovaporization of the prostate (TUVP) is effective, safe and durable. Prostate Cancer Prostatic Dis. https://doi.org/10.1038/sj.pcan.4500654
McNicholas TA, Woo HH, Chin PT et al (2013) Minimally invasive prostatic urethral lift: surgical technique and multinational experience. Eur Urol. https://doi.org/10.1016/j.eururo.2013.01.008
Porpiglia F, Fiori C, Bertolo R, Garrou D, Cattaneo G, Amparore D (2015) Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow-up. BJU Int. https://doi.org/10.1111/bju.12982
Gilling P, Anderson P, Tan A (2017) Aquablation of the prostate for symptomatic benign prostatic hyperplasia: 1-year results. J Urol. https://doi.org/10.1016/j.juro.2017.01.056
McVary KT, Gange SN, Gittelman MC et al (2016) Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. https://doi.org/10.1016/j.juro.2015.10.181
Ray AF, Powell J, Speakman MJ et al (2018) Efficacy and safety of prostate artery embolization for benign prostatic hyperplasia: an observational study and propensity-matched comparison with transurethral resection of the prostate (the UK-ROPE study). BJU Int. https://doi.org/10.1111/bju.14249
Magistro G, Stief CG, Gratzke C (2015) New intraprostatic injectables and prostatic urethral lift for male LUTS. Nat Rev Urol. https://doi.org/10.1038/nrurol.2015.169
Christidis D, McGrath S, Perera M, Manning T, Bolton D, Lawrentschuk N (2017) Minimally invasive surgical therapies for benign prostatic hypertrophy: The rise in minimally invasive surgical therapies. Prostate Int. https://doi.org/10.1016/j.prnil.2017.01.007
Patelli G, Ranieri A, Paganelli A, Mauri G, Pacella CM (2017) Transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: a feasibility study. Cardiovasc Intervent Radiol. https://doi.org/10.1007/s00270-017-1662-9
Pacella CM, Patelli G, Iapicca G et al (2019) Transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: a feasibility study. Results at 6 and 12 months from a retrospective multi-centric study. Prostate Cancer Prostatic Dis. https://doi.org/10.1038/s41391-019-0196-4
Porpiglia F, Fiori C, Amparore D et al (2019) Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-up. BJU Int. https://doi.org/10.1111/bju.14608
Gilling P, Reuther R, Kahokehr A, Fraundorfer M (2016) Aquablation - Image-guided robot-assisted waterjet ablation of the prostate: Initial clinical experience. BJU Int. https://doi.org/10.1111/bju.13358
McVary KT, Roehrborn CG (2018) Three-year outcomes of the prospective, randomized controlled rezūm system study: convective radiofrequency thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Urology. https://doi.org/10.1016/j.urology.2017.10.023
Pisco JM, Bilhim T, Costa NV et al (2020) Randomised clinical trial of prostatic artery embolisation versus a sham procedure for benign prostatic hyperplasia [formula presented]. Eur Urol. https://doi.org/10.1016/j.eururo.2019.11.010
Nguyen DD, Barber N, Bidair M et al (2020) Waterjet ablation therapy for endoscopic resection of prostate tissue trial (WATER) vs WATER II: comparing aquablation therapy for benign prostatic hyperplasia in 30–80 and 80–150 mL prostates. BJU Int. https://doi.org/10.1111/bju.14917
Elterman D, Bach T, Rijo E et al (2020) Transfusion rates after 800 aquablation procedures using various haemostasis methods. BJU Int. https://doi.org/10.1111/bju.14990
Venkatramani V, Panda A, Manojkumar R, Kekre NS (2014) Monopolar versus bipolar transurethral resection of bladder tumors: a single center, parallel arm, randomized, controlled trial. J Urol. https://doi.org/10.1016/j.juro.2013.12.004
Bach T, Giannakis I, Bachmann A et al (2019) Aquablation of the prostate: single-center results of a non-selected, consecutive patient cohort. World J Urol. https://doi.org/10.1007/s00345-018-2509-y
No funds are requested.
Conflict of interest
The authors have no relevant financial or non-financial interests to disclose.
Research involving human participants and/or animals
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study. Patients signed informed consent regarding publishing their data and photographs.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Frego, N., Saita, A., Casale, P. et al. Feasibility, safety, and efficacy of ultrasound-guided transperineal laser ablation for the treatment of benign prostatic hyperplasia: a single institutional experience. World J Urol 39, 3867–3873 (2021). https://doi.org/10.1007/s00345-021-03685-7